Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

Zacks
Open on Zacks
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

Agenus AGEN reported third-quarter 2026 earnings of 2 cents per share, in line with the Zacks Consensus Estimate.

Revenues in the quarter rose 4.3% year over year to $31.5 million but missed the Zacks Consensus Estimate of $35 million. Lower sequential revenues from pre-commercial botensilimab (BOT) +balstilimab (BAL) product sales and non-cash royalties weighed on quarterly performance.

The stock fell 7.6% yesterday, likely reflecting investors’ disappointment over the revenue miss, despite earnings meeting expectations.

Year to date, shares of Agenus have surged 105.1% compared with the industry’s 13.1% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

AGEN’s Q3 Results in Detail

Agenus’ lead program is BOT, a multifunctional, Fc-enhanced anti-CTLA-4 antibody, being developed both as a monotherapy and in combination with BAL, an anti-PD-1 antibody.

Pre-commercial BOT+BAL product revenues totaled $6 million in the third quarter, down 6.3% sequentially from $6.4 million in the second quarter. These revenues came from regulatory-authorized patient-access programs, including France's AAC framework and physician-initiated paid named-patient programs where permitted.

Non-cash royalty revenues totaled $25.5 million in the third quarter, down 12.4% from $29.1 million in the year-ago quarter. These royalties relate to previously monetized interests and do not generate cash for the company.

Agenus ended September 2026 with $86.9 million in cash, cash equivalents and short-term investments, up from $18.7 million as of June 30, 2026, supported by an oversubscribed private placement completed in July.

The company expects the financing to support the initiation of clinical studies, regulatory activities and corporate operations through the third quarter of 2027. Assuming full warrant exercise, the financing could support the planned ROBBIN development program and company operations through the end of 2031.

Agenus' Regulatory & Clinical Progress

In October 2026, the Ministry of Health of the Republic of Armenia granted separate marketing approvals for BOT and BAL, branded as Botvymo and Evamplix, respectively, for use together in previously treated adults with microsatellite-stable (MSS) metastatic colorectal cancer without active liver metastases. The approvals are conditional and renewable annually. They mark the first-ever marketing authorizations for both drugs worldwide. The combination remains investigational outside Armenia.

Meanwhile, Agenus continues to expand patient access through France's reimbursed compassionate-access program and physician-initiated named-patient programs in international markets.

Agenus is advancing preparations for its global phase III ROBBIN study evaluating BOT+BAL in patients with high-risk Stage II and Stage III MSS colon cancer. The company expects to dose the first patient in the first quarter of 2027, with interim pathologic response data anticipated in the second half of the year.

During the quarter, two phase II studies, NEST and UNICORN, showed encouraging results for Agenus' BOT+BAL combination in patients with MSS colon cancer before surgery. Both studies showed that around 30% of patients had no detectable cancer remaining in the treated tumor tissue.No recurrences had been reported at the latest update, although follow-up remains limited. These findings could support further evaluation of BOT+BAL in the upcoming ROBBIN study.

Agenus Inc. Price, Consensus and EPS Surprise

Agenus Inc. Price, Consensus and EPS Surprise

Agenus Inc. price-consensus-eps-surprise-chart | Agenus Inc. Quote

AGEN’s Zacks Rank & Stocks to Consider

Agenus currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are TG Therapeutics TGTX, currently sporting a Zacks Rank #1 (Strong Buy), and ImmunityBio IBRX and Amneal Pharmaceuticals AMRX, carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for TG Therapeutics have risen from 92 cents to 94 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from $2.65 to $2.66. TGTX’s shares have risen 94.5% year to date.

TG Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining one, with an average surprise of 184.65%.

Over the past 30 days, loss per share estimates for ImmunityBio remain unchanged at 97 cents for 2026. Over the same period, estimates for 2027 loss per share have improved from 14 cents to 11 cents. IBRX’s shares have skyrocketed 304.6% year to date.

ImmunityBio’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 13.40%.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.04 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.19. AMRX’s shares have climbed 54.4% year to date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Agenus Inc. (AGEN): Free Stock Analysis Report
 
TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report
 
AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis Report
 
ImmunityBio, Inc. (IBRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research